Tectonic Therapeutic (NASDAQ:TECX) Receives New Coverage from Analysts at SVB Leerink

SVB Leerink started coverage on shares of Tectonic Therapeutic (NASDAQ:TECX) in a research report report published on Wednesday morning, Benzinga reports. The firm issued an outperform rating and a $49.00 target price on the stock.

A number of other equities analysts have also recently commented on the stock. TD Cowen initiated coverage on shares of Tectonic Therapeutic in a research note on Monday, June 24th. They set a buy rating for the company. Piper Sandler initiated coverage on shares of Tectonic Therapeutic in a research note on Wednesday, June 26th. They set an overweight rating and a $76.00 price target for the company.

Tectonic Therapeutic Stock Performance

Tectonic Therapeutic stock opened at $17.64 on Wednesday. Tectonic Therapeutic has a twelve month low of $12.12 and a twelve month high of $19.80. The stock has a market capitalization of $791.86 million, a PE ratio of 25.57 and a beta of 2.63.

Tectonic Therapeutic (NASDAQ:TECX) last posted its earnings results on Thursday, May 9th. The company reported ($0.15) earnings per share for the quarter. On average, equities analysts forecast that Tectonic Therapeutic will post -4.24 earnings per share for the current fiscal year.

About Tectonic Therapeutic

Avrobio, Inc is a bio-technology company. It develops step-change cell and gene therapies for the treatment of cancer and rare disease. The company operates primarily in the United States and Canada. Avrobio, Inc is based in MA, United States.